Harvoni-hepcinat lp (90 mg Ledipasvir / 400 mg Sofosbuvir): Check Drug Details and Specifications

Indication

Harvoni is used for the treatment of chronic hepatitis C virus (HCV).

Cure rates are 94% to 99% in people infected with genotype 1 (46% of HCV cases). It has also been evaluated for the treatment of infection with other Hepatitis C genotypes, and has shown promising results in genotypes 3 and 4.

Note

SIDE EFFECT :

• Common side effects include muscle pains, headache, nausea, rash, diarrhea, insomnia and cough.
• More severe reactions are connected with allergic reactions to the medications and cardiovascular problems.

INTERACTIONS :

• Patients are advised to stay away from H2 Receptor Antagonists (H2RA) and Proton Pump Inhibitors (PPI) because they decrease the concentration of Ledipasvir.
• Ledipasvir / Sofosbuvir should additionally be avoided when taking Amiodarone or other drugs that lower heart rate; there is a serious risk of the heart slowing or stopping when Ledipasvir / Sofosbuvir is used with such drugs.

OVERDOSE :

• Do not use more than prescribed dose.
• If you suspect you may have overdosed, call your healthcare provider.
• Do not take extra dose to make up for the missed dose.

Precaution

• Harvoni is a prescription drug and should be used under proper medical guidance and advice.
• Do not use Harvoni if you are pregnant or breastfeeding or trying to get pregnant.
• Harvoni is contradicted for use during unprotected sexual intercourse as it may also lead to birth defects.